About Metrion Biosciences

Metrion Biosciences

Metrion Biosciences is a UK-based Contract Research Organization specialising in high quality ion channel screening and drug development expertise. We aim to provide our customers with access to a range of in vitro screening services that includes cardiac safety (hERG, CiPA panel of human cardiac ion channels) and neurotoxicology testing and phenotypic assays on a fee-for-service or collaboration basis.

We pride ourselves on being able to provide a flexible and cost effective service with an unparalleled level of expertise. Collectively, our management team have amassed over 80 years of experience in ion channel drug discovery and our clients can access this high level of expertise as part of our dedicated service.

Drug Development

Metrion Biosciences Invests in New High Throughput Screening Capability and Expanded Facilities

November 30 2022

Metrion Biosciences, the specialist ion channel contract research and drug discovery company, has announced the […]

Appointments

Metrion Biosciences Appoints Dr Benedetta Montagnini as Head of European Business Development

June 9 2022

Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, today […]

Diseases

Metrion Biosciences and Bioqube Ventures Collaborate on Venture Creation Project to Identify Novel Ion Channel Inhibitors for Autoimmune Diseases

December 16 2021

Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, and Bioqube Ventures […]